8-K: Q32 Bio Completes Enrollment in SIGNAL-AA Part B Trial

Q32 Bio Inc. announced the completion of enrollment for Part B of its SIGNAL-AA Phase 2a clinical trial for bempikibart in alopecia areata, exceeding its target with 33 patients.

Summary

• Q32 Bio Inc. completed enrollment in Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe alopecia areata (AA).
• The trial exceeded its initial target enrollment of approximately 20 patients, enrolling a total of 33 patients due to strong demand from patients and healthcare providers.
• Bempikibart is a fully human anti-IL-7R antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling.
• Part B involves a loading regimen of 200mg of bempikibart dosed weekly for four doses, followed by a maintenance dose of 200mg every-other-week over a 32-week period, for a total dosing period of 36 weeks.
• Efficacy will be evaluated based on mean percentage change from baseline in Severity of Alopecia Tool (SALT) scores and the proportion of subjects achieving various SALT improvements at week 36, with follow-up through week 52.
• Emerging signs of clinical activity are being observed amongst the early-enrolling patients in Part B of the trial.
• Preliminary pharmacokinetic data from Part B indicates that steady state concentration of the drug is achieved at least nine weeks earlier compared to Part A, potentially inducing earlier responsiveness.
• 墾,
• positives": [ "Completed enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial for bempikibart in alopecia areata.
• Exceeded the initial target enrollment of approximately 20 patients, enrolling a total of 33 patients, reflecting strong interest from patients and healthcare providers.
• Emerging signs of clinical activity are being observed among early-enrolling patients in Part B.
• Preliminary pharmacokinetic data from Part B shows steady state concentration of the drug is achieved at least nine weeks earlier than in Part A, potentially leading to earlier responsiveness.
• Bempikibart demonstrated encouraging clinical activity, a well-tolerated safety and tolerability profile, and expected on-mechanism changes in T-cells in Part A.
• The trial is intended to support advancement into pivotal trials upon completion, pending review of the results.

Sentiment

Score: 8

Explanation: The completion of enrollment, especially exceeding the target, and early positive signs, are strong indicators. The slight delay in data readout due to over-enrollment is a minor negative against the overall positive progress.

Risks

• Additional data or results of ongoing data analyses, including emerging signs of clinical activity and pharmacokinetic data, may not support current beliefs and expectations for bempikibart, particularly regarding the durability of clinical responses.
• Ongoing and future clinical studies, including Part B of the SIGNAL-AA Phase 2a clinical trial, may not be completed by mid-2026 or at all.
• Clinical studies might be more costly than expected or might not yield anticipated results.
• Q32 Bio may use its capital resources sooner than currently anticipated.
• Other risks and uncertainties identified in Q32 Bio's periodic, current, and other filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

Future Outlook

Q32 Bio expects to report topline data from Part B of the SIGNAL-AA trial in mid-2026. Pending these results, the company anticipates that the findings could support advancement into pivotal trials for bempikibart in alopecia areata.

Management Comments

• "We are pleased to complete enrollment and exceed our initial enrollment target in Part B of the SIGNAL-AA trial, which reflects our team's capabilities to execute our clinical development plan and the strong interest from patients and their healthcare providers in bempikibart's IL-7R antagonist approach in AA." Jodie Morrison, Chief Executive Officer of Q32 Bio.
• "In SIGNAL-AA Part A, bempikibart demonstrated encouraging clinical activity, a well-tolerated safety and tolerability profile, and expected on-mechanism changes in T-cells, indicative of potent IL-7 inhibition." Jodie Morrison, Chief Executive Officer of Q32 Bio.
• "Patients with AA are in need of new, safer, and more durable treatment alternatives to currently approved agents, and this milestone underscores our commitment to advancing bempikibart as a potentially differentiated therapeutic option." Jodie Morrison, Chief Executive Officer of Q32 Bio.
• "We look forward to sharing topline data from Part B of the SIGNAL-AA trial next year, which, pending the results, could support advancement into pivotal trials upon completion." Jodie Morrison, Chief Executive Officer of Q32 Bio.

Industry Context

The announcement highlights the ongoing need for new, safer, and more durable treatment alternatives for alopecia areata, a condition affecting approximately 700,000 people in the United States with limited current options. Q32 Bio's bempikibart, targeting IL-7 and TSLP pathways, positions it within the competitive landscape of autoimmune disease therapies, seeking to offer a differentiated therapeutic option.

Stakeholder Impact

• Shareholders: Positive impact due to successful clinical trial progress, increased patient interest, and potential for earlier drug responsiveness, which could de-risk the development pathway.
• Patients with Alopecia Areata: Potential for a new, safer, and more durable treatment option, addressing an unmet medical need.
• Healthcare Providers: Increased interest and potential for a new therapeutic tool for managing severe or very severe AA.

Next Steps

• Continue treatment of patients in Part B of the SIGNAL-AA trial for 36 weeks, with follow-up out to 52 weeks.
• Report topline data from Part B of the SIGNAL-AA trial in mid-2026.
• Pending results, advance bempikibart into pivotal trials for alopecia areata.

Key Dates

Recommendation

The successful completion of enrollment, significantly exceeding the target, for a Phase 2a clinical trial of a novel therapy for a condition with unmet needs is a strong positive signal. The observed early clinical activity and improved pharmacokinetic profile in Part B further de-risk the asset. While there's a slight delay in topline data due to over-enrollment, this is generally viewed as a positive problem. The potential for advancement to pivotal trials positions the company for significant future value creation, making it an attractive investment for long-term growth.

Keywords

Alopecia Areata, Bempikibart, SIGNAL-AA, Phase 2a Clinical Trial, Autoimmune Disease, Biotechnology, IL-7R Antibody, Q32 Bio